EUVIMEDEUVIMED entdecken
QuerschnittstudieOpen Access · CC BY-NC 4.0

Adherence of PARP inhibitor for frontline maintenance therapy in primary epithelial ovarian cancer: a cross-sectional survey

Ji Hyun Kim iD, Yumi Lee iD, Da-Young Kim iD, Sinae Kim iD, Sang-Soo Seo iD, Sokbom Kang iD, Sang-Yoon Park iD, Myong Cheol Lim iD

Journal of Gynecologic Oncology · 2024

DOI: 10.3802/jgo.2024.35.e3 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift Journal of Gynecologic Oncology, 2024. Verfasst von Ji Hyun Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Gynecologic Cancer, National Cancer Center, Goyang, Korea. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Korea Health Industry Development Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To identify the adherence rate to poly (ADP-ribose) polymerase (PARP) inhibitors and identify factors contributing to the deterioration of adherence at our institution. METHODS: The adherence rate to PARP inhibitors was calculated using self-reported Adherence to Refills and Medications Scale questionnaires from a cross-sectional survey. Multivariable logistic regression analysis was performed to identify the factors that affected adherence. RESULTS: Of the 131 respondents, 32 (24.4%) showed non-adherence to PARP inhibitors. In the multivariable logistic regression analysis, unemployed or retired status (odds ratio [OR]=4.878; 95% confidence interval [CI]=1.528-15.572; p=0.008), patients receiving niraparib (OR=3.387; 95% CI=1.283-8.940; p=0.014), and a lower score on the quality-of-life assessment (EORTC-QLQ-OV28), which reflects a better quality of life (QOC) with a lower symptom burden (OR=1.056; 95% CI=1.027-1.086; p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsAntineoplastic AgentsHumansFemaleCarcinoma, Ovarian EpithelialPoly(ADP-ribose) Polymerase InhibitorsCross-Sectional StudiesQuality of Life

Stichwörter der Autor:innen

ComplianceOvarian CancerPARP InhibitorSurvey

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Center for Gynecologic Cancer, National Cancer Center, Goyang, Korea.
  • Department of Nursing, Pukyong National University, Busan, Korea.
  • Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
  • Biostatistics Collaboration Team, Research Core Center, National Cancer Center, Goyang, Korea.
  • Rare & Pediatric Cancer Branch and Immuno-oncology Branch, Division of Rare and Refractory Cancer, Research Institute, National Cancer Center, Goyang, Korea.
  • Center for Clinical Trial, Hospital, National Cancer Center, Goyang, Korea. mclim@ncc.re.kr.

ORCID-Profile: Ji Hyun Kim, Yumi Lee, Da-Young Kim, Sinae Kim, Sang-Soo Seo, Sokbom Kang, Sang-Yoon Park, Myong Cheol Lim

Förderung

  • Korea Health Industry Development Institute

Zitieren

APA

Kim, J. H., Lee, Y., Kim, D. Y., Kim, S., Seo, S. S., Kang, S., Park, S. Y., & Lim, M. C. (2024). Adherence of PARP inhibitor for frontline maintenance therapy in primary epithelial ovarian cancer: a cross-sectional survey. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2024.35.e3

Vancouver

Kim JH, Lee Y, Kim DY, Kim S, Seo SS, Kang S, et al. Adherence of PARP inhibitor for frontline maintenance therapy in primary epithelial ovarian cancer: a cross-sectional survey. Journal of Gynecologic Oncology. 2024. doi:10.3802/jgo.2024.35.e3

BibTeX
@article{Kim2024,
  author = {Kim, Ji Hyun and Lee, Yumi and Kim, Da-Young and Kim, Sinae and Seo, Sang-Soo and Kang, Sokbom and Park, Sang-Yoon and Lim, Myong Cheol},
  title = {Adherence of PARP inhibitor for frontline maintenance therapy in primary epithelial ovarian cancer: a cross-sectional survey},
  journal = {Journal of Gynecologic Oncology},
  year = {2024},
  doi = {10.3802/jgo.2024.35.e3}
}
Kostenlos starten →